ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO397

Does Hemodialysis Weaken GDF-15 Impairing Pulmonary Hypertension in Chronic Kidney Failure?

Session Information

Category: Dialysis

  • 801 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Tang, Yifang, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
  • Zhou, Zhu, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
Background

Pulmonary hypertension (PH) is a common complication of chronic renal failure (CRF) and contributes to mortality. However, the occurrence of mechanism or risk factors in CRF complicated with PH remains unclear.

Methods

One hundred and twenty subjects were prospectively recruited and divided into CRF group (n=79) and control group (n=41). The CRF group were subsequently divided into the pre-hemodialysis group (n=41) and the hemodialysis group (n=38). The GDF-15 levels of all subjects were tested by ELISA. The levels of GDF-15 in groups were compared each other. The association between GDF-15 and other clinical parameters was analyzed as well as the association between pulmonary artery pressure (PAP) and other factors with the stepwise regression analysis.

Results

GDF-15 levels in CRF group were significantly higher than that in control group. There was no difference between pre-hemodialysis and hemodialysis groups. Positive correlations between GDF-15 and PAP, urea, creatinine, or uric acid (UA) were found with or without adjusting for age, sex, and body mass index (BMI). Additionally, GDF-15 was positively associated with PAP or creatinine. Moreover, PAP was positively associated with hypertension other than GDF-15, while negatively with total bilirubin (TBIL) or glucose (GLU).

Conclusion

GDF-15 is significantly elevated and positively associated with PAP in CRF patients. GDF-15 may be a therapeutic target for PH in CRF. Hemodialysis can’t weaken GDF-15 impairing PH because there is no difference in plasma levels of GDF-15 between pre-hemodialysis and hemodialysis patients with CRF. Moreover, PAP is negatively associated with TBIL or GLU in CRF.

Funding

  • Government Support – Non-U.S.